论文部分内容阅读
目的:探讨雌二醇氮芥联合拉司太特化疗对雄激素抵抗性前列腺癌的疗效。方法:选择12例已进行正规内分泌治疗≥3个疗程,病变呈进展趋势的患者,采用雌二醇氮芥与拉司太特联和化疗。结果:经1～3年随访,8例骨转移者治疗后症状均有不同程度缓解,复查骨扫描好转5例(62.5%),稳定3例(37.5%),中位有效期3个月,中位生存期23个月。结论:采用雌二醇氮芥与拉司太特(VP-16)联和化疗可提高患者生存质量及延长生存期。
Objective: To investigate the effect of estramustine combined with salmeterin on androgen-resistant prostate cancer. Methods: Twelve patients who had been treated for more than 3 cycles of formal endocrine therapy were enrolled in this study. The patients were treated with estramustine combined with busulfan and chemotherapy. Results: After 1 to 3 years of follow-up, 8 cases of bone metastasis were relieved to varying degrees after treatment. Five cases (62.5%) were recovered after bone scan and stable in 3 cases (37.5%). The median effective period was 3 months. Bit-life of 23 months. Conclusions: The combination of estramustine and laureth-5 (VP-16) can improve the quality of life and extend the survival of patients.